Immunotherapy of Osteosarcoma

This publication has 269 references indexed in Scilit:

• Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: A predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas
  European Journal of Cancer, 2012
• Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients
  Cancer Immunology, Immunotherapy, 2012
• Proton‐based radiotherapy for unresectable or incompletely resected osteosarcoma
  Cancer, 2011
• Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells
  Cancer Immunology, Immunotherapy, 2011
• Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma
  Pediatric Blood & Cancer, 2010
• Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma
  Cancer, 2009
• The Hospital for the Ruptured and Crippled: William Bradley Coley, Third Surgeon-in-Chief 1925–1933
  HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery, 2008
• Expression of a newly defined tumor‐rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I‐restricted cytotoxic T lymphocytes by SART3‐derived peptides
  Journal of Orthopaedic Research, 2001
• Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma
  Journal of Surgical Oncology, 1998
• In vitro and in vivo canine mononuclear cell production of tumor necrosis factor induced by muramyl peptides and lipopolysaccharide
  Veterinary Immunology and Immunopathology, 1993